

ppi. No. 09/839,574; Group Art Unit: 1646
 kt. No. 1530.0180002/EKS/EJH;
 inventors: Manthorpe *et al.*; Tel: 202/371-2600
 title: Compositions and Methods for in vivo Delivery of
 Oligonucleotide-Based Therapeutics

PLASMID
NAME

GENE

PARENTAL PROMOTOR/ TERMINATOR
PLASMID ENHANCER

VR1223	FIREFLY LUX	VR1012*	CMV	BGH
VR1412	BACTERIAL LACZ	VR1012*	CMV	BGH
VR2901	MOUSE EPO	VR1012*	CMV	BGH
VR2996	MOUSE EPO	VR1012	MV/Desmin	BGH
VR3301	HUMAN SEAP	VR1012*	CMV	BGH
VR3502	RAT PROINSULIN	VR1012*	CMV	BGH
VR4151	HUMAN IFN-OMEGA	VR1055	CMV	mRBG
VR4700	INFLUENZA NP	VR1255**	CMV	mRBG
VR1418	BACTERIAL LACZ	VR1043	RSV	BGH
VR1255	FIREFLY LUX	VR1223	CMV	mRBG

INTERMEDIATE PLASMIDS

VR1012	NONE	V1J***	CMV	BGH
VR1043	NONE	VR1343	RSV	BGH
VR1055	NONE	VR1255	CMV	mRBG

FIG. 1




FIG. 2A




FIG. 2B





FIG. 2C

FIG. 2D




FIG.3




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 5A




FIG. 5B




FIG. 5C




FIG.6A




FIG.6B



FIG.6C



FIG.6D




FIG.6E



FIG.6F




FIG. 7A




FIG. 7B




FIG. 8





FIG. 9




FIG. 10

pp. No. 09/839,574; Group Art Unit: 1646
kt. No. 1530.0180002/EKS/EJH;
nventors: Manthorpe *et al.*; Tel: 202/371-2600
itle: Compositions and Methods for in vivo Delivery of
olynucleotide-Based Therapeutics




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15







FIG. 16C



olymucopolysaccharide-Based Therapeutics
Title: Compositions and Methods for in vivo Delivery of
Inventors: Mamlihorpe et al.; Tel: 202/371-2600
R.R. No. 1500.018002/EKS/EJH
PPL No. 09/839,574; Group A in Unit: 1646

CTL ACTIVITY IS NOT INHIBITED WHEN pDNA +
POLOXAMER IS ADMINISTERED



EFFECTOR: TARGET

FIG. 16D

CLE EFFECTS ON IFN α pDNA MEDICATED ANTI-TUMOR EFFICACY




FIG. 17A





FIG. 17B

FIG. 18



oligonucleotide-Based Therapeutics
file: Compositions and Methods for in vivo Delivery of
nanotubes; Manthouze *et al.*; Tel: 202/371-2600
K1, No. 1530,0180002/EKS/EFH;
pp. No. 09/395,74; Group Amt Unit: 1646
Sheet 22 of 32





FIG. 19A

VR-1255 \pm POLOXAMER(S)

FIG. 19B



DAY 3 LUCIFERASE EXPRESSION AFTER INTRAMUSCULAR
ADMINISTRATION OF VR1255 \pm POLOXAMER (F68)





FIG. 20A


70027807-11255-25R2

DAY 3 LUCIFERASE EXPRESSION AFTER INTRAMUSCULAR
ADMINISTRATION OF VR1255 ± POLOXAMER (25R2)



Sheet 26 of 32
App. No. 09/839,54; Group Art Unit: 1646
Dkt. No. 1530.0118002/EKS/EH;
Inventors: Mathiopoulos et al.; TEL: 202/371-2600
Title: Compositions and Methods for in vivo Delivery of
Polymerotide-Based Therapeutics

FIG. 21



Sheet 27 of 32
Appl. No. 09/839,574; Group Art Unit: 1646
DK, No. 1530.018002/EKS/EJR;
Inventors: Manthoupe *et al.*; T-1: 202/371-2600
Title: Compositions and Methods for in vivo Delivery of
Poly nucleotide-Based Therapeutics

HCT LEVELS AFTER ADMINISTRATION OF VR2996 + POLOXAMER F68




FIG. 22

DNA DOSE RESPONSE AFTER INJECTION OF VR1255 \pm POLOXAMER

(25R2)




FIG. 23

புது தென்காந்தி திட்டத்தை வெளியிடுகிறேன்

TIME COURSE OF EXPRESSION AFTER DELIVERY OF
VR1255 ± 25R2 (0.01%)




FIG. 24

TRANSFECTION OF MOUSE RECTUS FEMORIS WITH VR1412 (pBgal) \pm
POLOXAMER 25R2 (0.01%)




FIG. 25

Targeted injections of 50 μ g β -gal pDNA
into murine rectus femoris
(10 μ m section stained with x-gal)




FIG. 26